Brief: Graviton Bioscience Announces Clearance Of Investigational New Drug For GV101 For The Treatment Of Friedreich's Ataxia
11/08/2026 16:39
Aug 11 (Reuters) - MeiraGTx Holdings PLCMGTX.O : * GRAVITON BIOSCIENCE ANNOUNCES CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) FOR GV101 FOR THE TREATMENT OF FRIEDREICH'S ATAXIA * MEIRAGTX - ENROLLMENT FOR PHASE 2 GV101 TRIAL EXPECTED TO BEGIN IN Q1 2027 Source text:ID:nPn8VDHsJa Further company coverage:MGTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on MeiraGTx Holdings
See all newsU.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
MeiraGTx gains; reports over $200 mln in license revenue
MeiraGTx Holdings PLC reports results for the quarter ended June 30 - Earnings Summary
MeiraGTx Q2 revenue jumps on Reogen license revenue
Brief: Graviton Bioscience Announces Clearance Of Investigational New Drug For GV101 For Treatment Of Friedreich's Ataxia